-
食管癌是一种致死率较高的恶性肿瘤,我国是食管癌发病率最高的国家之一,确诊和死亡人数均位居全球前列。根据国际流行病学的研究结果,目前我国食管癌的发病人数和死亡人数分别位于最常见癌症类型的第6位和第4位[1],食管癌在确诊时常常已是中晚期。目前根治性放化疗仍是无法行手术切除的食管癌患者最为有效的治疗方法之一[2]。食管癌放化疗联合手术治疗(chemoradiotherapy for oesophageal cancer followed by surgery study,CROSS)试验结果显示,食管鳞状细胞癌患者的病理学完全缓解(pathologic complete response,pCR)率高达49%[3]。在精准医学时代,如何评价早期食管癌患者放化疗的疗效成为临床亟待解决的难题。目前食管癌的疗效评价普遍采用实体瘤的疗效评价标准(response evaluation criteria in solid tumors,RECIST)1.1版[4],该标准以肿瘤病灶形态的变化为依据,但无法获取食管癌治疗前和治疗中瘤区血流灌注、血管通透性及微环境的变化。
功能MRI可以帮助医师在肿瘤体积发生变化之前观察到肿瘤的生物学和微观结构表征[5]。DWI能够提供反映肿瘤治疗前后肿瘤微环境变化的细胞学信息,而磁共振动态对比增强成像(dynamic contrast-enhanced magnetic resonance imaging,DCE-MRI)可以提供肿瘤微环境中的血流灌注和血管通透性信息。近年来,已有国内外研究者将DCE-MRI应用于食管癌放化疗的疗效评估[6-8]。前期我们利用DCE-MRI参数评估进展期食管癌患者的放化疗疗效,发现其灵敏度较高(90.9%),但特异度较低(54.5%)。目前DCE-MRI联合DWI-MRI功能成像参数评估进展期食管癌根治性放化疗早期疗效的研究文献报道较为少见。本研究旨在利用这两者的功能成像参数建立预测模型,评价其评估进展期食管癌治疗早期疗效的价值。
-
纳入的48例患者中,46例经组织病理学检查确诊为食管鳞癌、1例为食管腺癌、1例为食管小细胞癌。由表1可知,治疗有效组与无效组患者年龄和性别的差异均无统计学意义(均P>0.05)。治疗有效组和无效组患者T分期的差异有统计学意义(P<0.05)。治疗有效组和无效组患者癌胚抗原(CEA)水平、肿瘤位置、N分期的差异均无统计学意义(均P>0.05)。
参数 有效组(n=32) 无效组(n=16) χ2值 P值 年龄[岁,M(Q1,Q3)] 68(65,72) 66(63,73) − 0.449 性别(例,%) 1.500 0.221 男 14(43.8) 10(62.5) 女 18(56.3) 6(37.5) 癌胚抗原水平(例,%) 0.807 0.369 正常 24(75.0) 10(62.5) 升高 8(25.0) 6(37.5) 肿瘤位置(例,%) 0.098 0.755 颈段 7(21.9) 4(25.0) 颈胸上段 2(6.3) 3(18.8) 颈胸中段 0(0) 1(6.3) 胸上段 12(37.5) 1(6.3) 胸下段 0(0) 1(6.3) 胸中段 5(15.6) 3(18.8) 胸中上段 3(9.4) 1(6.3) 胸中下段 3(9.4) 2(12.5) T分期(例,%) 6.524 0.011 T3 11(34.4) 0(0) T4a 20(62.5) 15(93.8) T4b 1(3.1) 1(6.3) N分期(例,%) 3.799 0.051 N1 14(43.8) 3(18.8) N2 10(31.3) 5(31.3) N3 8(25.0) 8(50.0) 注:−表示无此项数据 表 1 48例进展期食管癌同步放化疗患者的一般资料
Table 1. General data of 48 patients diagnosed with locally advanced esophageal carcinoma
-
由表2可知,治疗有效组患者治疗前与治疗中Ktrans 、Kep 、ADC的差异均有统计学意义(均P<0.01)。由表3可知,治疗无效组患者治疗前与治疗中ADC的差异有统计学意义(P=0.001)。
项目 Ktrans[min−1,M(Q1,Q3)] Kep(min−1, )$\bar x\pm s $ Ve[min−1,M(Q1,Q3)] ADC(×10−3 mm2/s, )$\bar x\pm s $ 治疗前 0.42(0.33,0.55) 3.13±0.96 1.62(1.28,2.12) 1.42±0.38 治疗中 0.31(0.20,0.45) 2.18±0.76 1.86(1.07,2.89) 2.30±0.43 检验值 Z=−2.820 t=4.383 Z=−0.081 t=−8.612 P值 0.006 <0.001 0.805 <0.001 注:DCE-MRI为磁共振动态对比增强成像;DWI-MRI为磁共振弥散加权成像;Ktrans为容量转移常数;Kep为速率常数;Ve为血管外细胞外间隙容积比;ADC为表观扩散系数 表 2 32例进展期食管癌同步放化疗治疗有效组患者治疗前、治疗中DCE-MRI、DWI-MRI参数的比较
Table 2. Comparison of dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging magnetic resonance imaging parameters before and during treatment in response group in 32 locally advanced esophageal carcinoma patients treated with concurrent chemoradiotherapy
项目 Ktrans[min−1,M(Q1,Q3)] Kep(min−1, )$\bar x\pm s $ Ve(min−1, )$\bar x\pm s $ ADC(×10−3 mm2/s, )$\bar x\pm s $ 治疗前 0.29(0.25,0.42) 2.49±1.23 1.94±1.11 1.14±0.21 治疗中 0.30(0.25,0.61) 2.19±1.14 1.99±0.89 1.63±0.44 检验值 Z=−0.641 t=0.731 t=−0.139 t=−3.887 P值 0.520 0.470 0.890 0.001 注:DCE-MRI为磁共振动态对比增强成像;DWI-MRI为磁共振弥散加权成像;Ktrans为容量转移常数;Kep为速率常数;Ve为血管外细胞外间隙容积比;ADC为表观扩散系数 表 3 16例进展期食管癌同步放化疗治疗无效组患者治疗前、治疗中DCE-MRI、DWI-MRI参数的比较
Table 3. Comparison of dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging-magnetic resonance imaging parameters before and during treatment in non-response group in 16 locally advanced esophageal carcinoma patients treated with concurrent chemoradiotherapy
-
由表4可知,治疗有效组患者治疗前Ktrans和ADC高于无效组治疗前Ktrans和ADC,且差异均有统计学意义(均P<0.05)。治疗有效组患者治疗中ADC、ΔADC高于无效组治疗中ADC和ΔADC,差异均有统计学意义(均P<0.01)。治疗有效组、无效组典型病例MRI图见图1、图2。
组别 治疗前Ktrans[min−1,M(Q1,Q3)] 治疗中Ktrans[min−1,M(Q1,Q3)] ΔKtrans[min−1,M(Q1,Q3)] 治疗前Kep
(min−1, )$\bar x\pm s$ 治疗中Kep
(min−1, )$\bar x\pm s $ ΔKep
(min−1, )$\bar x\pm s $ 有效组(n=32) 0.42(0.33,0.55) 0.31(0.20,0.45) −0.12(−0.25,0.30) 3.13±0.96 2.18±0.76 −0.95±1.03 无效组(n=16) 0.29(0.25,0.42) 0.30(0.25,0.61) −4.98(−0.13,0.24) 2.49±1.23 2.19±1.14 −0.31±1.24 检验值 Z=−2.909 Z=−0.569 Z=−1.815 t=−1.980 t=0.020 t=1.912 P值 0.007 0.519 0.081 0.054 0.984 0.060 组别 治疗前Ve[min−1,M(Q1,Q3)] 治疗中Ve
(min−1, )$\bar x\pm s $ ΔVe (min−1, )$\bar x\pm s $ 治疗前ADC
(×10−3 mm2/s, )$\bar x\pm s $ 治疗中ADC
(×10−3 mm2/s, )$\bar x\pm s $ ΔADC
(×10−3 mm2/s, )$\bar x\pm s $ 有效组(n=32) 1.62(1.28,2.12) 1.87±0.94 0.03±1.25 1.42±0.38 2.30±0.43 0.86±0.39 无效组(n=16) 1.72(1.14,2.34) 1.99±0.89 0.05±1.31 1.14±0.21 1.63±0.44 0.45±0.49 检验值 Z=−0.066 t=0.424 t=0.053 t=−3.244 t=−5.013 t=−3.068 P值 0.717 0.674 0.958 0.020 <0.001 0.004 注:DCE-MRI为磁共振动态对比增强成像;DWI-MRI为磁共振弥散加权成像;Ktrans为容量转移常数;ΔKtrans为治疗中与治疗前Ktrans的差值;Kep为速率常数;ΔKep为治疗中与治疗前Kep的差值;Ve为血管外细胞外间隙容积比;ΔVe为治疗中与治疗前Ve的差值;ADC为表观扩散系数;ΔADC为治疗中与治疗前ADC的差值 表 4 48例进展期食管癌同步放化疗患者治疗有效组与无效组DCE-MRI、DWI-MRI参数的比较(
±s)$\bar x $ Table 4. Comparison of dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging-magnetic resonance imaging parameters between response and non-response groups in 48 locally advanced esophageal carcinoma patients treated with concurrent chemoradiotherapy (
±s)$\bar x $ -
单因素Logistic回归分析结果显示,治疗前Ktrans、ADC,ΔKtrans,治疗中ADC,ΔADC是同步放化疗疗效的影响因素(均P<0.05)(表5)。 将筛选出的治疗前Ktrans、ADC,ΔKtrans,治疗中ADC,ΔADC纳入多因素二元Logistic回归模型分析,结果显示,治疗中ADC是治疗有效的独立预测因素(95%CI:1.331~81.220,AUC=0.892,P=0.026)(表6,图3)。
因素 优势比 95%CI P值 治疗前Ktrans 1.093 1.021~1.171 0.011 ΔKtrans 0.968 0.939~0.997 0.032 治疗前ADC 18.304 1.606~208.659 0.019 治疗中ADC 22.678 3.920~131.211 <0.01 ΔADC 9.996 1.802~55.440 0.008 注:DCE-MRI为磁共振动态对比增强成像;DWI-MRI为磁共振弥散加权成像;Ktrans为容量转移常数;ΔKtrans为治疗中与治疗前Ktrans的差值;ADC为表观扩散系数;ΔADC为治疗中与治疗前ADC的差值;CI为置信区间 表 5 进展期食管癌同步放化疗患者DCE-MRI、DWI-MRI 参数预测放化疗疗效的单因素Logistic回归分析
Table 5. Results of univariate Logistic regression analysis of dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging magnetic resonance imaging parameters for predicting the efficacy of concurrent chemoradiotherapy in locally advanced esophageal carcinoma patients
因素 回归系数 标准误 Wald值 P值 OR值 95%CI 治疗前Ktrans 0.068 0.047 2.058 0.151 1.07 0.975~1.174 ΔKtrans 0.001 0.023 0.002 0.961 1.001 0.958~1.047 治疗前ADC 1.704 1.867 0.833 0.361 5.496 0.142~213.404 治疗中ADC 2.342 1.049 4.986 0.026 10.399 1.331~81.220 注:DCE-MRI为磁共振动态对比增强成像;DWI-MRI为磁共振弥散加权成像;Ktrans为容量转移常数;ΔKtrans为治疗中与治疗前Ktrans的差值;ADC为表观扩散系数;CI为置信区间 表 6 进展期食管癌同步放化疗患者DCE-MRI、DWI-MRI 参数预测放化疗疗效的多因素Logistic回归分析
Table 6. Results of multivariate Logistic regression analysis of dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging magnetic resonance imaging parameters for predicting the efficacy of concurrent chemoradiotherapy in locally advanced esophageal carcinoma patients
MRI动态对比增强成像及DWI联合应用对进展期食管癌同步放化疗早期疗效评估的价值
Predictive value of DWI-MRI combined with DCE-MRI on the early efficacy of concurrent chemoradiotherapy in locally advanced esophageal carcinoma
-
摘要:
目的 探讨MRI动态对比增强成像(DCE-MRI)联合磁共振弥散加权成像(DWI-MRI)在进展期食管癌同步放化疗患者早期疗效评价中的应用价值。 方法 回顾性分析2018年2月至2021年6月于江苏省肿瘤医院确诊的48例进展期食管癌患者放化疗治疗前、治疗第2~3周(治疗中)DWI-MRI和DCE-MRI的影像学及临床资料,其中男性24例、女性24 例,年龄(67.1±7.7)岁。根据实体瘤疗效评价标准(RESIST)(1.1版)将患者分为治疗有效组和无效组。采用配对样本t检验、Wilcoxon秩和检验比较容量转移常数(Ktrans)、速率常数(Kep)、血管外细胞外间隙容积比(Ve)、表观扩散系数(ADC)、Ktrans的差值(ΔKtrans)、Kep的差值(ΔKep)、Ve的差值(ΔVe)、ADC差值(ΔADC)在治疗前、治疗中的差异;采用独立样本t检验、Mann-Whitney U 检验比较Ktrans、Kep、Ve、ADC、ΔKtrans、ΔKep、ΔVe、ΔADC在治疗有效组、无效组之间的差异;计数资料的比较采用χ2检验或Kruskal-Wallis检验;采用单因素Logistic回归分析预测疗效的相关因素;采用多因素Logistic回归分析筛选出独立影响因素并建立疗效的预测模型,利用受试者工作特征(ROC)曲线评估模型的预测效能。 结果 48例患者中,治疗有效组32例、无效组16例。治疗有效组治疗前Ktrans高于无效组[0.42(0.33,0.55) min−1对0.29(0.25,0.42) min−1],差异有统计学意义(Z=−2.909,P=0.007);治疗有效组治疗前ADC高于无效组[(1.42±0.38)×10−3 mm2/s对(1.14±0.21)×10−3 mm2/s)]、治疗中ADC高于无效组[(2.30±0.43)×10−3 mm2/s对(1.63±0.44)×10−3 mm2/s]、ΔADC高于无效组[(0.86±0.39)×10−3 mm2/s对(0.45±0.49)×10−3 mm2/s],且差异均有统计学意义(t=−3.244、 −5.013、−3.068,均P<0.05)。单因素Logistic回归分析结果显示,治疗前Ktrans(OR=1.093,95%CI:1.021~1.171)、ΔKtrans(OR=0.968,95%CI:0.939~0.997)、治疗前ADC(OR=18.304,95%CI:1.606~208.659)、治疗中ADC(OR=22.678,95%CI:3.920~131.211)、ΔADC(OR=9.996,95%CI:1.802~55.440)是同步放化疗疗效的影响因素(均P<0.05);多因素二元Logistic回归分析结果显示,治疗中ADC是影响疗效的独立预测因素(95%CI:1.331~81.220,AUC=0.892,P=0.026)。 结论 DCE-MRI联合DWI-MRI参数预测模型可对进展期食管癌同步放化疗治疗效果进行早期评价。 -
关键词:
- 食管肿瘤 /
- 磁共振显像 /
- 磁共振动态对比增强成像 /
- 弥散加权成像 /
- 同步放化疗
Abstract:Objective To investigate the potential application of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) combined with diffusion-weighted imaging (DWI) in evaluating response to concurrent chemoradiotherapy (CCRT) in locally advanced esophageal carcinoma (EC). Methods The clinical data of 48 patients with locally advanced EC who were treated with CCRT at Jiangsu Cancer Hospital from February 2018 to June 2021 were retrospectively analyzed, including 24 males and 24 females, with an average age of (67.1±7.7) years. DCE-MRI and DWI-MRI were performed before and during CCRT (2–3 weeks). Patients were categorized into two groups, namely, the response group and non-response group, after 3 months of treatment in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The quantitative parameters of DCE-MRI (Ktrans, Kep, and Ve) and the changes in parameters (ΔKtrans, ΔKep, and ΔVe), as well as the quantitative parameter of DWI-MRI (apparent diffusion coefficient (ADC)) and the changes in ADC (ΔADC), were calculated and compared by using the paired sample t-test and Wilcoxon rank sum test before and during CCRT of the two groups, respectively. The independent sample t-test and Mann-Whitney U test were used to evaluate the differences between the response group and non-response group. Moreover, univariate and multivariate Logistic regression analysis were used to analyze the potential prognostic factors. Receiver operating characteristic curve was used to evaluate the efficiency of the prediction model. Results A total of 48 patients were divided into two groups: 32 in the response group and 16 in the non-response group. Ktrans before the start of CCRT in the response group was significantly higher than that in the non-response group (0.42(0.33, 0.55) min−1 vs. 0.29(0.25, 0.42) min−1, Z=−2.909, P=0.007), whereas ADC before the start of CCRT ((1.42±0.38)×10−3 mm2/s vs. (1.14±0.21)×10−3 mm2/s), ADC during CCRT ((2.30±0.43)×10−3 mm2/s vs. (1.63±0.44)×10−3 mm2/s), and ΔADC ((0.86±0.39)×10−3 mm2/s vs. (0.45±0.49)×10−3 mm2/s) also showed a remarkable difference between the two groups (t=−3.244, −5.013, −3.068; all P<0.05). Univariate Logistic regression analysis showed that Ktrans before the start of CCRT (OR=1.093, 95%CI: 1.021–1.171), ΔKtrans (OR=0.968, 95%CI: 0.939–0.997), ADC before the start of CCRT (OR=18.304, 95%CI: 1.606–208.659), ADC during CCRT (OR=22.678, 95%CI: 3.920–131.211), and ΔADC (OR=9.996, 95%CI: 1.802–55.440) were the potential prognostic factors for effective early treatment. Multivariable Logistic regression analysis showed that ADC during CCRT could be the best parameter to evaluate treatment performance (95%CI: 1.331–81.220, AUC=0.892, P=0.026). Conclusion The combination of DCE-MRI and DWI-MRI can be used in predicting response to CCRT in locally advanced EC. -
表 1 48例进展期食管癌同步放化疗患者的一般资料
Table 1. General data of 48 patients diagnosed with locally advanced esophageal carcinoma
参数 有效组(n=32) 无效组(n=16) χ2值 P值 年龄[岁,M(Q1,Q3)] 68(65,72) 66(63,73) − 0.449 性别(例,%) 1.500 0.221 男 14(43.8) 10(62.5) 女 18(56.3) 6(37.5) 癌胚抗原水平(例,%) 0.807 0.369 正常 24(75.0) 10(62.5) 升高 8(25.0) 6(37.5) 肿瘤位置(例,%) 0.098 0.755 颈段 7(21.9) 4(25.0) 颈胸上段 2(6.3) 3(18.8) 颈胸中段 0(0) 1(6.3) 胸上段 12(37.5) 1(6.3) 胸下段 0(0) 1(6.3) 胸中段 5(15.6) 3(18.8) 胸中上段 3(9.4) 1(6.3) 胸中下段 3(9.4) 2(12.5) T分期(例,%) 6.524 0.011 T3 11(34.4) 0(0) T4a 20(62.5) 15(93.8) T4b 1(3.1) 1(6.3) N分期(例,%) 3.799 0.051 N1 14(43.8) 3(18.8) N2 10(31.3) 5(31.3) N3 8(25.0) 8(50.0) 注:−表示无此项数据 表 2 32例进展期食管癌同步放化疗治疗有效组患者治疗前、治疗中DCE-MRI、DWI-MRI参数的比较
Table 2. Comparison of dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging magnetic resonance imaging parameters before and during treatment in response group in 32 locally advanced esophageal carcinoma patients treated with concurrent chemoradiotherapy
项目 Ktrans[min−1,M(Q1,Q3)] Kep(min−1, )$\bar x\pm s $ Ve[min−1,M(Q1,Q3)] ADC(×10−3 mm2/s, )$\bar x\pm s $ 治疗前 0.42(0.33,0.55) 3.13±0.96 1.62(1.28,2.12) 1.42±0.38 治疗中 0.31(0.20,0.45) 2.18±0.76 1.86(1.07,2.89) 2.30±0.43 检验值 Z=−2.820 t=4.383 Z=−0.081 t=−8.612 P值 0.006 <0.001 0.805 <0.001 注:DCE-MRI为磁共振动态对比增强成像;DWI-MRI为磁共振弥散加权成像;Ktrans为容量转移常数;Kep为速率常数;Ve为血管外细胞外间隙容积比;ADC为表观扩散系数 表 3 16例进展期食管癌同步放化疗治疗无效组患者治疗前、治疗中DCE-MRI、DWI-MRI参数的比较
Table 3. Comparison of dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging-magnetic resonance imaging parameters before and during treatment in non-response group in 16 locally advanced esophageal carcinoma patients treated with concurrent chemoradiotherapy
项目 Ktrans[min−1,M(Q1,Q3)] Kep(min−1, )$\bar x\pm s $ Ve(min−1, )$\bar x\pm s $ ADC(×10−3 mm2/s, )$\bar x\pm s $ 治疗前 0.29(0.25,0.42) 2.49±1.23 1.94±1.11 1.14±0.21 治疗中 0.30(0.25,0.61) 2.19±1.14 1.99±0.89 1.63±0.44 检验值 Z=−0.641 t=0.731 t=−0.139 t=−3.887 P值 0.520 0.470 0.890 0.001 注:DCE-MRI为磁共振动态对比增强成像;DWI-MRI为磁共振弥散加权成像;Ktrans为容量转移常数;Kep为速率常数;Ve为血管外细胞外间隙容积比;ADC为表观扩散系数 表 4 48例进展期食管癌同步放化疗患者治疗有效组与无效组DCE-MRI、DWI-MRI参数的比较(
±s)$\bar x $ Table 4. Comparison of dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging-magnetic resonance imaging parameters between response and non-response groups in 48 locally advanced esophageal carcinoma patients treated with concurrent chemoradiotherapy (
±s)$\bar x $ 组别 治疗前Ktrans[min−1,M(Q1,Q3)] 治疗中Ktrans[min−1,M(Q1,Q3)] ΔKtrans[min−1,M(Q1,Q3)] 治疗前Kep
(min−1, )$\bar x\pm s$ 治疗中Kep
(min−1, )$\bar x\pm s $ ΔKep
(min−1, )$\bar x\pm s $ 有效组(n=32) 0.42(0.33,0.55) 0.31(0.20,0.45) −0.12(−0.25,0.30) 3.13±0.96 2.18±0.76 −0.95±1.03 无效组(n=16) 0.29(0.25,0.42) 0.30(0.25,0.61) −4.98(−0.13,0.24) 2.49±1.23 2.19±1.14 −0.31±1.24 检验值 Z=−2.909 Z=−0.569 Z=−1.815 t=−1.980 t=0.020 t=1.912 P值 0.007 0.519 0.081 0.054 0.984 0.060 组别 治疗前Ve[min−1,M(Q1,Q3)] 治疗中Ve
(min−1, )$\bar x\pm s $ ΔVe (min−1, )$\bar x\pm s $ 治疗前ADC
(×10−3 mm2/s, )$\bar x\pm s $ 治疗中ADC
(×10−3 mm2/s, )$\bar x\pm s $ ΔADC
(×10−3 mm2/s, )$\bar x\pm s $ 有效组(n=32) 1.62(1.28,2.12) 1.87±0.94 0.03±1.25 1.42±0.38 2.30±0.43 0.86±0.39 无效组(n=16) 1.72(1.14,2.34) 1.99±0.89 0.05±1.31 1.14±0.21 1.63±0.44 0.45±0.49 检验值 Z=−0.066 t=0.424 t=0.053 t=−3.244 t=−5.013 t=−3.068 P值 0.717 0.674 0.958 0.020 <0.001 0.004 注:DCE-MRI为磁共振动态对比增强成像;DWI-MRI为磁共振弥散加权成像;Ktrans为容量转移常数;ΔKtrans为治疗中与治疗前Ktrans的差值;Kep为速率常数;ΔKep为治疗中与治疗前Kep的差值;Ve为血管外细胞外间隙容积比;ΔVe为治疗中与治疗前Ve的差值;ADC为表观扩散系数;ΔADC为治疗中与治疗前ADC的差值 表 5 进展期食管癌同步放化疗患者DCE-MRI、DWI-MRI 参数预测放化疗疗效的单因素Logistic回归分析
Table 5. Results of univariate Logistic regression analysis of dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging magnetic resonance imaging parameters for predicting the efficacy of concurrent chemoradiotherapy in locally advanced esophageal carcinoma patients
因素 优势比 95%CI P值 治疗前Ktrans 1.093 1.021~1.171 0.011 ΔKtrans 0.968 0.939~0.997 0.032 治疗前ADC 18.304 1.606~208.659 0.019 治疗中ADC 22.678 3.920~131.211 <0.01 ΔADC 9.996 1.802~55.440 0.008 注:DCE-MRI为磁共振动态对比增强成像;DWI-MRI为磁共振弥散加权成像;Ktrans为容量转移常数;ΔKtrans为治疗中与治疗前Ktrans的差值;ADC为表观扩散系数;ΔADC为治疗中与治疗前ADC的差值;CI为置信区间 表 6 进展期食管癌同步放化疗患者DCE-MRI、DWI-MRI 参数预测放化疗疗效的多因素Logistic回归分析
Table 6. Results of multivariate Logistic regression analysis of dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging magnetic resonance imaging parameters for predicting the efficacy of concurrent chemoradiotherapy in locally advanced esophageal carcinoma patients
因素 回归系数 标准误 Wald值 P值 OR值 95%CI 治疗前Ktrans 0.068 0.047 2.058 0.151 1.07 0.975~1.174 ΔKtrans 0.001 0.023 0.002 0.961 1.001 0.958~1.047 治疗前ADC 1.704 1.867 0.833 0.361 5.496 0.142~213.404 治疗中ADC 2.342 1.049 4.986 0.026 10.399 1.331~81.220 注:DCE-MRI为磁共振动态对比增强成像;DWI-MRI为磁共振弥散加权成像;Ktrans为容量转移常数;ΔKtrans为治疗中与治疗前Ktrans的差值;ADC为表观扩散系数;CI为置信区间 -
[1] Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783−791. DOI: 10.1097/CM9.0000000000001474. [2] Ajani JA, D'Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2019, 17(7): 855−883. DOI: 10.6004/jnccn.2019.0033. [3] Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015, 16(9): 1090−1098. DOI: 10.1016/S1470-2045(15)00040-6. [4] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228−247. DOI: 10.1016/j.ejca.2008.10.026. [5] Wang L, Liu LH, Han C, et al. The diffusion-weighted magnetic resonance imaging (DWI) predicts the early response of esophageal squamous cell carcinoma to concurrent chemoradiotherapy[J]. Radiother Oncol, 2016, 121(2): 246−251. DOI: 10.1016/j.radonc.2016.10.021. [6] Heethuis SE, Goense L, van Rossum PSN, et al. DW-MRI and DCE-MRI are of complementary value in predicting pathologic response to neoadjuvant chemoradiotherapy for esophageal cancer[J]. Acta Oncol, 2018, 57(9): 1201−1208. DOI: 10.1080/0284186X.2018.1473637. [7] Heethuis SE, van Rossum PSN, Lips IM, et al. Dynamic contrast-enhanced MRI for treatment response assessment in patients with oesophageal cancer receiving neoadjuvant chemoradiotherapy[J]. Radiother Oncol, 2016, 120(1): 128−135. DOI: 10.1016/j.radonc.2016.05.009. [8] Sun NN, Liu C, Ge XL, et al. Dynamic contrast-enhanced MRI for advanced esophageal cancer response assessment after concurrent chemoradiotherapy[J]. Diagn Interv Radiol, 2018, 24(4): 195−202. DOI: 10.5152/dir.2018.17369. [9] Yang H, Liu H, Chen YP, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase Ⅲ multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018, 36(27): 2796−2803. DOI: 10.1200/JCO.2018.79.1483. [10] Nam SY, Jeon SW, Lee SJ, et al. Clinical factors to predict the response to concurrent chemoradiotherapy and survival in esophageal cancer patients[J]. Gut Liver, 2020, 14(4): 450−458. DOI: 10.5009/gnl19165. [11] Dubois LJ, Niemans R, van Kuijk SJA, et al. New ways to image and target tumour hypoxia and its molecular responses[J]. Radiother Oncol, 2015, 116(3): 352−357. DOI: 10.1016/j.radonc.2015.08.022. [12] Gaustad JV, Hauge A, Wegner CS, et al. DCE-MRI of tumor hypoxia and hypoxia-associated aggressiveness[J/OL]. Cancers, 2020, 12(7): 1979[2022-04-12]. https://www.mdpi.com/2072-6694/12/7/1979. DOI: 10.3390/cancers12071979. [13] Ye ZM, Dai SJ, Yan FQ, et al. DCE-MRI-derived volume transfer constant (Ktrans) and DWI apparent diffusion coefficient as predictive markers of short- and long-term efficacy of chemoradiotherapy in patients with esophageal cancer[J]. Technol Cancer Res Treat, 2018, 17: 1533034618765254. DOI: 10.1177/1533034618765254. [14] Borggreve AS, Heethuis SE, Boekhoff MR, et al. Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer[J]. Eur Radiol, 2020, 30(4): 1896−1907. DOI: 10.1007/s00330-019-06513-0. [15] John NO, Irodi A, Thomas HMT, et al. Utility of mid-treatment DWI in selecting pathological responders to neoadjuvant chemoradiotherapy in locally advanced esophageal cancer[J/OL]. J Gastrointest Cancer, 2022[2022-04-12]. https://link.springer.com/article/10.1007/s12029-022-00818-y. DOI: 10.1007/s12029-022-00818-y. [published online ahead of print March 26, 2022] [16] Maffazzioli L, Zilio MB, Klamt AL, et al. ADC as a predictor of pathologic response to neoadjuvant therapy in esophageal cancer: a systematic review and meta-analysis[J]. Eur Radiol, 2020, 30(7): 3934−3942. DOI: 10.1007/s00330-020-06723-x. [17] Aoyagi T, Shuto K, Okazumi S, et al. Apparent diffusion coefficient correlation with oesophageal tumour stroma and angiogenesis[J]. Eur Radiol, 2012, 22(6): 1172−1177. DOI: 10.1007/s00330-011-2359-0. [18] Aoyagi T, Shuto K, Okazumi S, et al. Apparent diffusion coefficient values measured by diffusion-weighted imaging predict chemoradiotherapeutic effect for advanced esophageal cancer[J]. Dig Surg, 2011, 28(4): 252−257. DOI: 10.1159/000328770. [19] Borggreve AS, Goense L, van Rossum PSN, et al. Preoperative prediction of pathologic response to neoadjuvant chemoradiotherapy in patients with esophageal cancer using 18F-FDG PET/CT and DW-MRI: a prospective multicenter study[J]. Int J Radiat Oncol Biol Phys, 2020, 106(5): 998−1009. DOI: 10.1016/j.ijrobp.2019.12.038. [20] Beukinga RJ, Wang D, Karrenbeld A, et al. Addition of HER2 and CD44 to 18F-FDG PET-based clinico-radiomic models enhances prediction of neoadjuvant chemoradiotherapy response in esophageal cancer[J]. Eur Radiol, 2021, 31(5): 3306−3314. DOI: 10.1007/s00330-020-07439-8. [21] 王坚, 于静萍, 汪建林, 等. 非手术食管癌患者放化疗中肿瘤组织病理反应和血清血管内皮生长因子的变化及其对预后的影响[J]. 中华肿瘤杂志, 2016, 38(8): 589−595. DOI: 10.3760/cma.j.issn.0253-3766.2016.08.005.
Wang J, Yu JP, Wang JL, et al. Pathologic response and changes of serum VEGF during chemoradiotherapy may predict prognosis in non-surgical patients with esophageal carcinoma[J]. Chin J Oncol, 2016, 38(8): 589−595. DOI: 10.3760/cma.j.issn.0253-3766.2016.08.005.